Clinical update on the management of atrial fibrillation

Pharmacotherapy

Volumn 33, Issue 4, 2013, Pages 422-446

  Danelich, Ilya M ^a   Reed, Brent N ^b   Hollis, Ian B ^b   Cook, Abigail M ^d   Rodgers, Jo E ^c  

^a Rochester Methodist Hospital   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Catheter ablation; New anticoagulants; Rate versus rhythm; Upstream therapy

Indexed keywords

ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; ATORVASTATIN; CLOPIDOGREL; CREATININE; DABIGATRAN; DABIGATRAN ETEXILATE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; DRONEDARONE; FATTY ACID DERIVATIVE; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; PLACEBO; POLYUNSATURATED FATTY ACID; PROPAFENONE; RENIN INHIBITOR; RIVAROXABAN; VERNAKALANT; WARFARIN;

ALCOHOL CONSUMPTION; ARTICLE; ATRIOVENTRICULAR BLOCK; BLEEDING; BRADYCARDIA; BRAIN HEMORRHAGE; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE CONTROL; DISEASE PREDISPOSITION; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; DYSGEUSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; INTERNATIONAL NORMALIZED RATIO; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; PARESTHESIA; PREVALENCE; PRIMARY PREVENTION; SCORING SYSTEM; SECONDARY PREVENTION; SIDE EFFECT; SINUS RHYTHM; SNEEZING; THROMBOEMBOLISM; THYROID DISEASE; TORSADE DES POINTES; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; FATTY ACIDS, UNSATURATED; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC;

EID: 84879582170     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1217     Document Type: Article

References (113)

1. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-1539.
2. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988.
4. Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community- based study. J Am Coll Cardiol 2007;49:986-992.
5. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines: developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-e354.
6. RealiseAF. Real life global survey evaluating patients with atrial fibrillation. Realise AF Registry, September 2010. Available from https://www.realiseaf.org/getdoc/7ea883ec-c5dc-466d-af28-e1efdb07a881/ Presentation-Stegg.aspx. Accessed April 10, 2012.
7. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000;356:1789-1794.
8. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.
9. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840.
10. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm control in persistent atrial fibrillation. J Am Coll Cardiol 2003;41:1690-1696.
11. Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with atrial fibrillation: the results of the Polish How to Treat Chronic Atrial (HOT CAFE) Study. Chest 2004;126:476-486.
12. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-2677.
13. Ogawa S, Yamashita T, Yamazaki T, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 2009;73:242-248.
14. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109:1509-1513.
15. Pedersen OD, Bagger H, Keller N, Marchant B, Køber L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) substudy. Circulation 2001;104:292-296.
16. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-1373.
17. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/ HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:104-123.
18. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-2870.
19. You JJ, Singer DE, Howard PA, et al. Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(suppl 2):e531S-e575S.
20. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010;137:263-272.
21. 2-VASc scoring systems for guiding antithrombotic treatment of patients with atrial fibrillation: review of the literature and recommendations for use. Pharmacotherapy 2012;32:285-296.
22. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010;123:638-645.
23. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-99.
24. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144-152.
25. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006;130:1390-1396.
26. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713-719.
27. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-1100.
28. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011;57:173-180.
29. McMillin GA, Vazquez SR, Pendleton RC. Current challenges in personalizing warfarin therapy. Expert Rev Clin Pharmacol 2011;4:349-362.
30. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009;15:244-252.
31. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
32. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
33. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
34. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-1912.
35. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-2078.
36. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-817.
37. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-1876.
38. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172:397-402.
39. Ezekowitz MD, Reilly PA, Wallentin L, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007;100:1419-1426.
40. Institute of Safe Medication Practices. ISMP medication safety alert, May 31 12, 2012.
41. Institute of Safe Medication Practices. ISMP medication safety alert, January 12, 2012.
42. Boehringer Ingelheim. Pradaxa (dabigatran) package insert. Ridgefield, CT; 2012.
43. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation: supplementary appendix, August 2011. Available from http://www.nejm.org/doi/suppl/10.1056/NEJMoa1009638/suppl-file/ nejmoa1009638-appendix.pdf. Accessed March 15, 2012.
44. Janssen. Xarelto (rivaroxaban) package insert. Gurabo, PR; 2011.
45. Khan I. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003;87:121-128.
46. Azpitarte J, Alvarez M, Baun O, et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur Heart J 1997;18:1649-1654.
47. Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P. Amiodarone versus placebo and classic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003;41:255-262.
48. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation 2000;102:2385-2390.
49. Fedida D, Orth PM, Chen JY, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2005;16:1227-1238.
50. Mao ZL, Wheeler JJ, Clohs L, Beatch GN, Keirns J. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol 2009;49:17-29.
51. Roy D, Rowe BH, Stiell IG, et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004;44:2355-2361.
52. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008;117:1518-1525.
53. Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo- controlled trial. Circ Arrhythm Electrophysiol 2009;2:652-659.
54. Pratt CM, Roy D, Torp-Pedersen C, et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol 2010;106:1277-1283.
55. Stiell IG, Roos JS, Kavanagh KM, Dickinson G. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J 2010;159: 1095-1101.
56. Camm AJ, Capucci A, Hohnloser SH, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011;57:313-321.
57. Oyetayo OO, Rogers CE, Hofmann PO. Dronedarone: a new antiarrhythmic agent. Pharmacotherapy 2010;30:904-915.
58. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-2687.
59. Connolly SJ, Camm AJ, Hohnloser SH, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268-2276.
60. Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008;156:527. e1-e9.
61. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 2003;24:1481-1487.
62. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357:987-999.
63. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-678.
64. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallelgroup study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010;21:597-605.
65. Sanofi-Aventis. Multaq (dronedarone) package insert. Ambares, France; 2011.
66. Sanofi-aventis. Risk evaluation and mitigation strategy (REMS): Multaq (dronedarone). August 5, 2011.
67. Food and Drug Administration. FDA drug safety communication: Severe liver injury associated with the use of dronedarone (marketed as Multaq). January 14, 2011.
68. Gilead Sciences. A study to evaluate the effect of ranolazine and dronedarone when given alone and in combination in patients with paroxysmal atrial fibrillation (HARMONY). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine (US). 2000. Available from http://clinicaltrials.gov/ct2/ show/NCT01522651NLMIdentifier:NCT01522651. Accessed May 9, 2012.
69. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non STsegment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;16:1647-1652.
70. Bunch TJ, Mahapatra S, Murdock D, et al. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing Clin Electrophysiol 2011;34:1600-1606.
71. Burashnikov A, Sicouri S, Di Diego JM, Belardinelli L, Antzelevitch C. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol 2010;56:1216-1224.
72. Wazni O, Wilkoff B, Saliba W. Catheter ablation for atrial fibrillation. N Engl J Med 2011;365:2296-2304.
73. Morillo C, Verma A, Kuck KH, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: (RAAFT 2): a randomized trial. Heart Rhythm Society 2012 Scientific Sessions, 2012; Boston, MA. Abstract LB02-1.
74. Mayo Clinic. Catheter Ablation versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation trial (CABANA). ClinicalTrials. gov [Internet]. Bethesda, MD: National Library of Medicine (US), 2000. Available from http:// clinicaltrials.gov/ct2/show/NCT00911508NLMIdentifier:NCT00911508. Accessed March 17, 2012.
75. Noheria A, Kumar A, Wylie JV Jr, Josephson ME. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systemic review. Arch Intern Med 2008;168:581-586.
76. Piccini JP, Lopes RD, Kong MH, Hasselblad V, Jackson K, Al-Khatib SM. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a metaanalysis of randomized, controlled trials. Circ Arrhythm Electrophysiol 2009;2:626-633.
77. Rordorf R, Savastano S, Gandolfi E, Vicentini A, Petracci B, Landolina M. Pharmacological therapy following catheter ablation of atrial fibrillation. J Cardiovasc Med 2012;13:9-15.
78. Calò L, Martino A, Sciarra L, et al. Upstream effect for atrial fibrillation: still a dilemma? Pacing Clin Electrophysiol 2011;34:111-128.
79. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 2011;13:308-328.
80. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace 2011;13:610-625.
81. Makkar KM, Sanoski CA, Spinler SA. Role of angiotensinconverting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Pharmacotherapy 2009;29:31-48.
82. Ducharme A, Schiffrin EL. Reviewing the future of reninangiotensin system blockade: the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the prevention of atrial fibrillation. Can J Cardiol 2010;26 (suppl E):21E-23E.
83. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-380.
84. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003;107:2926-2931.
85. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val- HeFT). Am Heart J 2005;149:548-557.
86. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-1839.
87. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006;152:217-222.
88. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther 2008;15:36-43.
89. Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin- angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010;55:2299-2307.
90. Salehian O, Healey J, Stambler B, et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation Study. Am Heart J 2007;154:448-453.
91. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin- receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008;372:1174-1183.
92. White CM, Kluger J, Lertsburapa K, Faheem O, Coleman CI. Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the Atrial FIbrillation Suppression Trials II and III. Eur J Cardiothorac Surg 2007;31:817-820.
93. Shariff N, Zelenkofske S, Eid S, Weiss MJ, Mohammed MQ. Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after CABG surgery. BMC Cardiovasc Disord 2010;10:7.
94. Coleman CI, Makanji S, Kluger J, White CM. Effect of angiotensin- converting enzyme inhibitors or angiotensin receptor blockers on the frequency of postcardiothoracic surgery atrial fibrillation. Ann Pharmacother 2007;41:433-437.
95. Ozaydin M, Dede O, Varol E, et al. Effect of renin-angiotensin aldosteron system blockers on postoperative atrial fibrillation. Int J Cardiol 2008;127:362-367.
96. Lee YL, Blaha MJ, Jones SR. Statin therapy in the prevention and treatment of atrial fibrillation. J Clin Lipidol 2011;5:18-29.
97. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. The effect of simvastatin and antioxidant vitamins on atrial fibrillation- promotion by atrial tachycardia remodeling in dogs. Circulation 2004;110:2313-2319.
98. Shiroshita-Takeshita A, Brundel BJ, Burstein B, et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 2007;74:75-84.
99. Dickinson MG, Ip JH, Olshansky B, et al. Statin therapy was associated with reduced atrial fibrillation and flutter in heart failure patients in SCD-HEFT. Heart Rhythm 2006;3:S49 (Abstract).
100. Maggioni AP, Fabbri G, Lucci D, et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI- HF trial. Eur Heart J 2009;19:2327-2336.
101. Kotlewski A, Liu ILA, Khan SS, Shen AY, Brar SS. Prevalence of atrial fibrillation and flutter by different HMG-CoA reductase inhibitors and doses in heart failure. J Am Coll Cardiol 2006;47:61A (Abstract).
102. Izzo R, de Simone G, Trimarco V, et al. Statins therapy and atrial fibrillation in hypertensive patients [Abstract 2997]. Circulation 2008;118:II-802 (Abstract).
103. Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:705-711.
104. Macfarlane PW, Murray H, Sattar N, et al. The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. Europace 2011;13:634-639.
105. Adabag AS, Nelson DB, Bloomfield HE. Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. Am Heart J 2007;154:1140-1145.
106. Vedre A, Gurm HS, Froehlich JB, et al. Impact of prior statin therapy on arrhythmic events in patients with acute coronary syndromes (from the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol 2009;104:1613-1617.
107. Schwartz GG, Olsson AG, Chaitman B, Goldberg J, Szarek M, Sasiela WJ. Effect of intensive statin treatment on the occurrence of atrial fibrillation after acute coronary syndrome: an analysis of the MIRACL trial. Circulation 2004;110:III-740 (Abstract).
108. Schwartz GG, Chaitman BR, Goldberger JJ, Messig M. Effect of high-dose atorvastatin on risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Circulation 2010;122:Abstract 10897.
109. Liakopoulos OJ, Choi YH, Kuhn EW, et al. Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. J Thorac Cardiovasc Surg 2009;138:678-686.
110. Chen WT, Krishnan GM, Sood N, Kluger J, Coleman CI. Effects of statins on atrial fibrillation after cardiac surgery: a duration- and dose-response meta-analysis. J Thorac Cardiovasc Surg 2010;140:364-372.
111. Savelieva I, Camm AJ. Polyunsaturated fatty acids for prevention of atrial fibrillation: a 'fishy' story. Europace 2011;13:149-152.
112. Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation 2004;110:368-373.
113. Macchia A, Monte S, Pellegrini F, et al. Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. Eur J Clin Pharmacol 2008;64:627-634.